256
Participants
Start Date
November 11, 2022
Primary Completion Date
December 1, 2023
Study Completion Date
December 1, 2023
Trastuzumab deruxtecan
No drug will be administered during this study.
ICO Girona, Girona
Breast Center Humanitas Cancer Center IRCCS Istituto Clinico Humanitas, Rozzano
Hospital Universitario de Jaen, Jaén
Hospital Clínico San Carlos, Madrid
Hospital 12 de Octubre, Madrid
Hospital Universitario La Paz, Madrid
Centro di riferimento Oncologico (CRO), National Cancer Institute, Aviano
Institute Oncology Veneto, Padua
Hospital Universitario Virgen del Rocio, Seville
Fundacion Instituto Valenciano de Oncologia, Valencia
National Cancer Instutute 'Fondazione Pascale, Naples
St. Vincent's Private Hospital, Dublin
St. Vincent's University Hospital, Dublin
Universita Campus Bio-Medico Di Roma, Rome
Policlinico Umberto I Di Roma, Rome
Fondazione Policlinico Univeritario Agostino Gemeli, Rome
Hospital General Universitario De Alicante, Alicante
Hospital Del Mar, Barcelona
Hospital Quiron Salud Barcelona, Barcelona
Hospital Val d'Hebron, Barcelona
Hospital Clinic de Barcelona, Barcelona
Lead Sponsor
Daiichi Sankyo
INDUSTRY